Ocugen (OCGN) Interest & Investment Income (2016 - 2026)
Ocugen's (OCGN) quarterly Interest & Investment Income came in at $100000.0 in Q1 2026, down 66.67% YoY from $300000.0 in Q1 2025, and down 65.87% on a QoQ basis from $293000.0 in Q4 2025.
Powered by 
Analysis
Ocugen (OCGN) Interest & Investment Income (2016 - 2026) Analysis & Trends
Ocugen (OCGN) has 8 years of Interest & Investment Income data on file, last reported at $100000.0 in Q1 2026.
- Quarterly Interest & Investment Income fell 66.67% year-over-year to $100000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $900000.0 (down 18.55% YoY) and the FY2025 annual result came in at $922000.0, down 29.08% from the prior year.
- Interest & Investment Income slipped to $100000.0 in Q1 2026, from $293000.0 in the prior quarter.
- In the past five years, Interest & Investment Income ranged from a high of $500000.0 in Q4 2024 to a low of $100000.0 in Q1 2026.
- A 3-year average of $283333.3 and a median of $296500.0 in 2024 frame the typical range for Interest & Investment Income.
- Annual changes were most pronounced in 2025 — Interest & Investment Income sank 31.0% — and 2026, when it slumped 66.67%.
- Tracing OCGN's Interest & Investment Income over 3 years: stood at $500000.0 in 2024, then sank by 41.4% to $293000.0 in 2025, then plunged by 65.87% to $100000.0 in 2026.
- The last three Interest & Investment Income figures came in at $100000.0 (Q1 2026), $293000.0 (Q4 2025), and $207000.0 (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 67.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 35.58 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 27.90 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 28.14 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 5.13 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 10.98 Mn |
| 10 | Ocugen | 458.91 Mn | 358.81 Mn | - | 400,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 400,000.00 |
| Mar 31, 2026 | 132,000.00 |
| Dec 31, 2025 | 122,000.00 |
| Sep 30, 2025 | 207,000.00 |
| Jun 30, 2025 | 227,000.00 |
| Mar 31, 2025 | 343,000.00 |
| Dec 31, 2024 | 457,000.00 |
| Sep 30, 2024 | 310,000.00 |
| Jun 30, 2024 | 173,000.00 |
| Mar 31, 2024 | 302,000.00 |
| Sep 30, 2021 | 5,000.00 |
| Jun 30, 2021 | 10,000.00 |
| Dec 31, 2020 | 1,065.00 |
| Mar 31, 2020 | 119.00 |
| Dec 31, 2019 | 107.00 |
| Sep 30, 2019 | 136.00 |
| Jun 30, 2019 | 377.00 |
| Mar 31, 2019 | 594.00 |
| Dec 31, 2018 | 1,820.00 |
| Sep 30, 2018 | 3,762.00 |